- Latest
- Trending
Research Highlights:
Embargoed until 12:30 p.m. CT/1:30 p.m. ET Saturday, June 6
DALLAS, JUNE 6, 2026— Among adults with both obesity and an autoimmune disease, those taking a glucagon-like peptide-receptor 1 agonist (GLP-1RA) medication had lower rates of emergency department visits and were less likely to experience serious cardiac events, such as stroke, pulmonary embolism or death when compared to similar adults who were not taking these medications, according to new research published today in the Journal of the American Heart Association, an open-access, peer-reviewed journal of the American Heart Association. This research was presented at the American Diabetes Association 2026 Scientific Sessions in New Orleans on Saturday, June 6 at 12:30 p.m. CT/1:30 p.m. CT, abstract number 2199-P.
GLP-1RA therapies are commonly prescribed for weight-loss and to manage blood sugar levels in people with Type 2 diabetes. This new study examines the heart health benefits of GLP-1RAs for people with both obesity and at least one autoimmune disease to determine if there is a reduction in serious cardiac events or other positive cardiovascular benefits.
Obesity and autoimmune disease are each associated with a higher risk of cardiovascular and blood clot events. This is the first study to examine the effects of GLP-1RAs on people with both obesity and other types of autoimmune disease, including gastrointestinal (e.g. celiac disease), skin (e.g. vitiligo), endocrine (e.g. Type 1 diabetes) or musculoskeletal disease (e.g. rheumatoid or psoriatic arthritis).
“This is a high-risk population, and historically we’ve had limited data to guide treatment decisions,” said Amy Sheer, M.D., M.P.H., an associate professor of medicine and director of the Obesity Medicine Fellowship program at the University of Florida in Gainesville, Florida. “In this real-world analysis, we found a consistent signal toward fewer serious complications including blood clots and lower mortality among patients treated with GLP-1RA. Our research broadens the conversation around GLP-1RA. For clinicians, we hope these findings may prompt a more thoughtful, individualized approach when considering these therapies in higher-risk patients who have both obesity and autoimmune disease.”
“I am excited about the combination of medications for these diseases – pairing medicines with known benefits to treat the autoimmune disease with a GLP-1RA,” said Sheer. “For people who are overweight or living with obesity and an autoimmune disease, this study offers a hopeful signal that medications already in use today may be beneficial in reducing their risk of CVD.”
Researchers reviewed electronic health record data for more than 26,000 adults treated in the OneFlorida+ network from 2014 to 2024. Cardiac outcomes were analyzed for people taking a GLP-1RA medication vs. those who did not.
What are the study’s key findings?
“The 44% reduction in all-cause mortality observed among patients with obesity and co-occurring autoimmune disease is a striking finding that demands our attention,” said Fatima Cody Stanford, M.D., M.P.H., M.P.A., M.B.A., FAHA and member of the American Heart Association’s Lifestyle and Cardiometabolic Council.
“As an obesity medicine physician scientist who regularly cares for patients with complex inflammatory conditions, this study reinforces what many of us have suspected clinically — that the benefits of GLP-1 receptor agonists extend well beyond blood sugar control and weight loss and may fundamentally alter the disease trajectory for some of our highest-risk patients.”
Stanford, who was not involved in this research, is an obesity medicine physician scientist, educator and policy maker at Massachusetts General Hospital and Harvard Medical School, both in Boston.
What are the details, background, design and limitations of the study?
Study limitations include that because the analysis was a review of electronic health records it cannot prove cause and effect. In addition, autoimmune diseases are highly diverse, and this study primarily treated them as a broad group (the secondary analysis evaluated them in subgroups). Other factors, such as weight loss or improved blood sugar levels, may have contributed to the observed positive outcomes. More research is needed to investigate and evaluate the role of GLP-1-based medications as a treatment and preventative therapy for obesity and autoimmune disease.
Co-authors, disclosures and funding sources are listed in the manuscript.
Studies published in the American Heart Association’s scientific journals are peer-reviewed. The statements and conclusions in each manuscript are solely those of the study authors and do not necessarily reflect the Association’s policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. The Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and biotech companies, device manufacturers and health insurance providers and the Association’s overall financial information are available here.
Additional Resources:
About the American Heart Association
The American Heart Association is a relentless force for a world of longer, healthier lives. Dedicated to ensuring equitable health in all communities, the organization has been a leading source of health information for more than one hundred years. Supported by more than 35 million volunteers globally, we fund groundbreaking research, advocate for the public’s health, and provide critical resources to save and improve lives affected by cardiovascular disease and stroke. By driving breakthroughs and implementing proven solutions in science, policy, and care, we work tirelessly to advance health and transform lives every day. Connect with us on heart.org, Facebook, X or by calling 1-800-AHA-USA1.
###
For Media Inquiries and American Heart Association Expert Perspective:
Kelsey Beveridge: kelsey.beveridge@heart.org
For Public Inquiries: 1-800-AHA-USA1 (242-8721)
heart.org and stroke.org
The first sign that something unusual was unfolding in the Solomon Islands was when the Chinese police showed up at...
The next stage is for the Council to adopt its position on the Draft Budget, to which Parliament will respond,...
Mumbai: A man died and a woman had to be hospitalised reportedly after excessive alcohol intake at a concert in...
Discover Global News Panorama at news.mapworldnow.com — your universal gateway to comprehensive, international journalism. From politics and technology to culture and sports, we cover all news niches and all news categories from every corner of the world, all in one place.
